Which has higher valuation and earnings, VTRS or LNTH?

Lantheus has lower revenue, but higher earnings than Viatris. Viatris is trading at a lower price-to-earnings ratio than Lantheus, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Viatris $14.30B 1.46 -$3.51B -$0.36 N/A Lantheus $1.54B 4.23 $233.56M $4.14 24.15

Is VTRS or LNTH more profitable?

Lantheus has a net margin of 17.69% compared to Viatris' net margin of -2.79%. Lantheus' return on equity of 28.10% beat Viatris' return on equity. Company Net Margins Return on Equity Return on Assets Viatris -2.79% 20.02% 8.02% Lantheus 17.69% 28.10% 14.35%

Does the media refer more to VTRS or LNTH?

In the previous week, Viatris had 2 more articles in the media than Lantheus. MarketBeat recorded 10 mentions for Viatris and 8 mentions for Lantheus. Lantheus' average media sentiment score of 0.54 beat Viatris' score of 0.32 indicating that Lantheus is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Viatris 2 Very Positive mention(s) 0 Positive mention(s) 7 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Lantheus 1 Very Positive mention(s) 1 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media prefer LNTH or JAZZ?

In the previous week, Jazz Pharmaceuticals had 3 more articles in the media than Lantheus. MarketBeat recorded 11 mentions for Jazz Pharmaceuticals and 8 mentions for Lantheus. Lantheus' average media sentiment score of 0.54 beat Jazz Pharmaceuticals' score of 0.40 indicating that Lantheus is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Lantheus 1 Very Positive mention(s) 1 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Jazz Pharmaceuticals 3 Very Positive mention(s) 2 Positive mention(s) 4 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral

Does the media refer more to NBIX or LNTH?

In the previous week, Neurocrine Biosciences had 3 more articles in the media than Lantheus. MarketBeat recorded 11 mentions for Neurocrine Biosciences and 8 mentions for Lantheus. Neurocrine Biosciences' average media sentiment score of 0.54 beat Lantheus' score of 0.54 indicating that Neurocrine Biosciences is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Neurocrine Biosciences 3 Very Positive mention(s) 2 Positive mention(s) 3 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Positive Lantheus 1 Very Positive mention(s) 1 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Which has preferable valuation and earnings, LNTH or CORT?

Lantheus has higher revenue and earnings than Corcept Therapeutics. Lantheus is trading at a lower price-to-earnings ratio than Corcept Therapeutics, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Lantheus $1.54B 4.23 $233.56M $4.14 24.15 Corcept Therapeutics $761.41M 16.10 $99.65M $0.42 269.93

Does the media favor LNTH or CORT?

In the previous week, Corcept Therapeutics had 1 more articles in the media than Lantheus. MarketBeat recorded 9 mentions for Corcept Therapeutics and 8 mentions for Lantheus. Corcept Therapeutics' average media sentiment score of 0.62 beat Lantheus' score of 0.54 indicating that Corcept Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Lantheus 1 Very Positive mention(s) 1 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Corcept Therapeutics 2 Very Positive mention(s) 1 Positive mention(s) 5 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media refer more to LNTH or ELAN?

In the previous week, Lantheus had 4 more articles in the media than Elanco Animal Health. MarketBeat recorded 8 mentions for Lantheus and 4 mentions for Elanco Animal Health. Lantheus' average media sentiment score of 0.54 beat Elanco Animal Health's score of 0.40 indicating that Lantheus is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Lantheus 1 Very Positive mention(s) 1 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Elanco Animal Health 1 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Lantheus (LNTH) Competitors

$99.99 -0.01 (-0.01%)

Closing price 10/15/2026 04:00 PM Eastern

Extended Trading

$99.74 -0.24 (-0.25%)

As of 10/15/2026 07:30 PM Eastern

Compare

LNTH vs. VTRS, JAZZ, NBIX, CORT, and ELAN

Should you buy Lantheus stock or one of its competitors? Lantheus's main competitors and comparable companies include Viatris (VTRS), Jazz Pharmaceuticals (JAZZ), Neurocrine Biosciences (NBIX), Corcept Therapeutics (CORT), and Elanco Animal Health (ELAN). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "pharmaceuticals" industry.

How does Lantheus compare to Viatris?

Viatris (NASDAQ:VTRS) and Lantheus (NASDAQ:LNTH) are both healthcare companies, but which is the better investment? We will compare the two companies based on the strength of their institutional ownership, analyst recommendations, valuation, profitability, media sentiment, risk, dividends and earnings.

Viatris has a beta of 0.87, meaning that its share price is 13% less volatile than the broader market. Comparatively, Lantheus has a beta of -0.06, meaning that its share price is 106% less volatile than the broader market.

79.9% of Viatris shares are held by institutional investors. Comparatively, 99.1% of Lantheus shares are held by institutional investors. 0.3% of Viatris shares are held by insiders. Comparatively, 1.7% of Lantheus shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Lantheus has lower revenue, but higher earnings than Viatris. Viatris is trading at a lower price-to-earnings ratio than Lantheus, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Viatris	$14.30B	1.46	-$3.51B	-$0.36	N/A
Lantheus	$1.54B	4.23	$233.56M	$4.14	24.15

In the previous week, Viatris had 2 more articles in the media than Lantheus. MarketBeat recorded 10 mentions for Viatris and 8 mentions for Lantheus. Lantheus' average media sentiment score of 0.54 beat Viatris' score of 0.32 indicating that Lantheus is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Viatris	2 Very Positive mention(s)	0 Positive mention(s)	7 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Lantheus	1 Very Positive mention(s)	1 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Lantheus has a net margin of 17.69% compared to Viatris' net margin of -2.79%. Lantheus' return on equity of 28.10% beat Viatris' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Viatris	-2.79%	20.02%	8.02%
Lantheus	17.69%	28.10%	14.35%

Viatris presently has a consensus target price of $20.50, suggesting a potential upside of 12.51%. Lantheus has a consensus target price of $107.44, suggesting a potential upside of 7.46%. Given Viatris' stronger consensus rating and higher probable upside, equities analysts clearly believe Viatris is more favorable than Lantheus.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Viatris	0 Sell rating(s)	3 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.67
Lantheus	0 Sell rating(s)	11 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.21

Summary

Lantheus beats Viatris on 10 of the 16 factors compared between the two stocks.

How does Lantheus compare to Jazz Pharmaceuticals?

Lantheus (NASDAQ:LNTH) and Jazz Pharmaceuticals (NASDAQ:JAZZ) are both healthcare companies, but which is the superior investment? We will compare the two companies based on the strength of their dividends, risk, profitability, earnings, analyst recommendations, media sentiment, institutional ownership and valuation.

Lantheus has higher earnings, but lower revenue than Jazz Pharmaceuticals. Jazz Pharmaceuticals is trading at a lower price-to-earnings ratio than Lantheus, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Lantheus	$1.54B	4.23	$233.56M	$4.14	24.15
Jazz Pharmaceuticals	$4.60B	3.03	-$356.15M	$14.50	14.79

Lantheus has a beta of -0.06, suggesting that its share price is 106% less volatile than the broader market. Comparatively, Jazz Pharmaceuticals has a beta of 0.37, suggesting that its share price is 63% less volatile than the broader market.

In the previous week, Jazz Pharmaceuticals had 3 more articles in the media than Lantheus. MarketBeat recorded 11 mentions for Jazz Pharmaceuticals and 8 mentions for Lantheus. Lantheus' average media sentiment score of 0.54 beat Jazz Pharmaceuticals' score of 0.40 indicating that Lantheus is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Lantheus	1 Very Positive mention(s)	1 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Jazz Pharmaceuticals	3 Very Positive mention(s)	2 Positive mention(s)	4 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral

99.1% of Lantheus shares are owned by institutional investors. Comparatively, 89.1% of Jazz Pharmaceuticals shares are owned by institutional investors. 1.7% of Lantheus shares are owned by company insiders. Comparatively, 4.1% of Jazz Pharmaceuticals shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

Lantheus presently has a consensus target price of $107.44, indicating a potential upside of 7.46%. Jazz Pharmaceuticals has a consensus target price of $291.25, indicating a potential upside of 35.83%. Given Jazz Pharmaceuticals' stronger consensus rating and higher possible upside, analysts plainly believe Jazz Pharmaceuticals is more favorable than Lantheus.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Lantheus	0 Sell rating(s)	11 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.21
Jazz Pharmaceuticals	0 Sell rating(s)	1 Hold rating(s)	18 Buy rating(s)	1 Strong Buy rating(s)	3.00

Jazz Pharmaceuticals has a net margin of 20.45% compared to Lantheus' net margin of 17.69%. Jazz Pharmaceuticals' return on equity of 33.97% beat Lantheus' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Lantheus	17.69%	28.10%	14.35%
Jazz Pharmaceuticals	20.45%	33.97%	13.02%

Summary

Jazz Pharmaceuticals beats Lantheus on 11 of the 17 factors compared between the two stocks.

How does Lantheus compare to Neurocrine Biosciences?

Neurocrine Biosciences (NASDAQ:NBIX) and Lantheus (NASDAQ:LNTH) are both healthcare companies, but which is the better investment? We will contrast the two businesses based on the strength of their profitability, media sentiment, dividends, institutional ownership, risk, valuation, analyst recommendations and earnings.

In the previous week, Neurocrine Biosciences had 3 more articles in the media than Lantheus. MarketBeat recorded 11 mentions for Neurocrine Biosciences and 8 mentions for Lantheus. Neurocrine Biosciences' average media sentiment score of 0.54 beat Lantheus' score of 0.54 indicating that Neurocrine Biosciences is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Neurocrine Biosciences	3 Very Positive mention(s)	2 Positive mention(s)	3 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive
Lantheus	1 Very Positive mention(s)	1 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Neurocrine Biosciences has higher revenue and earnings than Lantheus. Neurocrine Biosciences is trading at a lower price-to-earnings ratio than Lantheus, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Neurocrine Biosciences	$3.37B	4.13	$478.60M	$6.82	20.08
Lantheus	$1.54B	4.23	$233.56M	$4.14	24.15

Neurocrine Biosciences has a beta of 0.4, meaning that its share price is 60% less volatile than the broader market. Comparatively, Lantheus has a beta of -0.06, meaning that its share price is 106% less volatile than the broader market.

Neurocrine Biosciences has a net margin of 20.91% compared to Lantheus' net margin of 17.69%. Lantheus' return on equity of 28.10% beat Neurocrine Biosciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Neurocrine Biosciences	20.91%	22.43%	15.64%
Lantheus	17.69%	28.10%	14.35%

Neurocrine Biosciences currently has a consensus price target of $201.14, indicating a potential upside of 46.87%. Lantheus has a consensus price target of $107.44, indicating a potential upside of 7.46%. Given Neurocrine Biosciences' stronger consensus rating and higher probable upside, equities research analysts clearly believe Neurocrine Biosciences is more favorable than Lantheus.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Neurocrine Biosciences	0 Sell rating(s)	4 Hold rating(s)	19 Buy rating(s)	1 Strong Buy rating(s)	2.88
Lantheus	0 Sell rating(s)	11 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.21

92.6% of Neurocrine Biosciences shares are owned by institutional investors. Comparatively, 99.1% of Lantheus shares are owned by institutional investors. 4.6% of Neurocrine Biosciences shares are owned by insiders. Comparatively, 1.7% of Lantheus shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

Summary

Neurocrine Biosciences beats Lantheus on 14 of the 17 factors compared between the two stocks.

How does Lantheus compare to Corcept Therapeutics?

Lantheus (NASDAQ:LNTH) and Corcept Therapeutics (NASDAQ:CORT) are both healthcare companies, but which is the superior stock? We will contrast the two companies based on the strength of their risk, analyst recommendations, valuation, profitability, dividends, institutional ownership, media sentiment and earnings.

Lantheus has a net margin of 17.69% compared to Corcept Therapeutics' net margin of 6.52%. Lantheus' return on equity of 28.10% beat Corcept Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Lantheus	17.69%	28.10%	14.35%
Corcept Therapeutics	6.52%	8.26%	6.45%

Lantheus currently has a consensus target price of $107.44, indicating a potential upside of 7.46%. Corcept Therapeutics has a consensus target price of $138.17, indicating a potential upside of 21.87%. Given Corcept Therapeutics' stronger consensus rating and higher probable upside, analysts plainly believe Corcept Therapeutics is more favorable than Lantheus.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Lantheus	0 Sell rating(s)	11 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.21
Corcept Therapeutics	1 Sell rating(s)	1 Hold rating(s)	5 Buy rating(s)	1 Strong Buy rating(s)	2.75

99.1% of Lantheus shares are held by institutional investors. Comparatively, 93.6% of Corcept Therapeutics shares are held by institutional investors. 1.7% of Lantheus shares are held by insiders. Comparatively, 20.7% of Corcept Therapeutics shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

Lantheus has a beta of -0.06, suggesting that its share price is 106% less volatile than the broader market. Comparatively, Corcept Therapeutics has a beta of 0.4, suggesting that its share price is 60% less volatile than the broader market.

Lantheus has higher revenue and earnings than Corcept Therapeutics. Lantheus is trading at a lower price-to-earnings ratio than Corcept Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Lantheus	$1.54B	4.23	$233.56M	$4.14	24.15
Corcept Therapeutics	$761.41M	16.10	$99.65M	$0.42	269.93

In the previous week, Corcept Therapeutics had 1 more articles in the media than Lantheus. MarketBeat recorded 9 mentions for Corcept Therapeutics and 8 mentions for Lantheus. Corcept Therapeutics' average media sentiment score of 0.62 beat Lantheus' score of 0.54 indicating that Corcept Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Lantheus	1 Very Positive mention(s)	1 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Corcept Therapeutics	2 Very Positive mention(s)	1 Positive mention(s)	5 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Summary

Corcept Therapeutics beats Lantheus on 10 of the 17 factors compared between the two stocks.

How does Lantheus compare to Elanco Animal Health?

Lantheus (NASDAQ:LNTH) and Elanco Animal Health (NYSE:ELAN) are both healthcare companies, but which is the superior investment? We will compare the two companies based on the strength of their earnings, media sentiment, valuation, dividends, risk, institutional ownership, analyst recommendations and profitability.

Lantheus currently has a consensus price target of $107.44, suggesting a potential upside of 7.46%. Elanco Animal Health has a consensus price target of $29.70, suggesting a potential upside of 26.31%. Given Elanco Animal Health's stronger consensus rating and higher possible upside, analysts plainly believe Elanco Animal Health is more favorable than Lantheus.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Lantheus	0 Sell rating(s)	11 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.21
Elanco Animal Health	1 Sell rating(s)	2 Hold rating(s)	8 Buy rating(s)	1 Strong Buy rating(s)	2.75

In the previous week, Lantheus had 4 more articles in the media than Elanco Animal Health. MarketBeat recorded 8 mentions for Lantheus and 4 mentions for Elanco Animal Health. Lantheus' average media sentiment score of 0.54 beat Elanco Animal Health's score of 0.40 indicating that Lantheus is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Lantheus	1 Very Positive mention(s)	1 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Elanco Animal Health	1 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

99.1% of Lantheus shares are held by institutional investors. Comparatively, 97.5% of Elanco Animal Health shares are held by institutional investors. 1.7% of Lantheus shares are held by insiders. Comparatively, 1.1% of Elanco Animal Health shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

Lantheus has a beta of -0.06, meaning that its stock price is 106% less volatile than the broader market. Comparatively, Elanco Animal Health has a beta of 1.7, meaning that its stock price is 70% more volatile than the broader market.

Lantheus has higher earnings, but lower revenue than Elanco Animal Health. Elanco Animal Health is trading at a lower price-to-earnings ratio than Lantheus, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Lantheus	$1.54B	4.23	$233.56M	$4.14	24.15
Elanco Animal Health	$4.72B	2.49	-$232M	-$0.41	N/A

Lantheus has a net margin of 17.69% compared to Elanco Animal Health's net margin of -3.96%. Lantheus' return on equity of 28.10% beat Elanco Animal Health's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Lantheus	17.69%	28.10%	14.35%
Elanco Animal Health	-3.96%	8.13%	3.99%

Summary

Lantheus beats Elanco Animal Health on 11 of the 17 factors compared between the two stocks.

Get Lantheus News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding LNTH and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

LNTH vs. The Competition

Export

Metric	Lantheus	Pharmaceuticals Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$6.53B	$12.47B	$7.31B	$12.93B
Dividend Yield	N/A	2.62%	2.51%	19.61%
P/E Ratio	20.08	644.31	206.61	19.70
Price / Sales	4.23	749.93	572.86	86.68
Price / Cash	15.66	83.43	76.19	51.56
Price / Book	6.09	9.32	10.32	6.01
Net Income	$233.56M	$2.84B	$3.50B	$380.68M
7 Day Performance	-0.16%	-3.80%	-3.34%	-3.15%
1 Month Performance	-0.55%	-6.99%	-6.61%	-5.18%
1 Year Performance	77.41%	-4.59%	2.69%	-4.07%

Lantheus Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
LNTH Lantheus	3.6637 of 5 stars	$99.99 0.0%	$107.44 +7.5%	+76.9%	$6.53B	$1.54B	20.08	1,193	Analyst Forecast
VTRS Viatris	2.9472 of 5 stars	$17.62 +0.1%	$20.50 +16.3%	+82.6%	$20.22B	$14.30B	N/A	30,000	Analyst Upgrade
JAZZ Jazz Pharmaceuticals	4.2495 of 5 stars	$236.04 +0.2%	$291.15 +23.3%	+57.9%	$15.30B	$4.27B	16.28	2,890
NBIX Neurocrine Biosciences	4.8326 of 5 stars	$144.21 +0.7%	$202.73 +40.6%	-0.6%	$14.55B	$2.86B	21.15	2,000	Analyst Upgrade
CORT Corcept Therapeutics	4.2674 of 5 stars	$122.03 +5.0%	$138.17 +13.2%	+47.6%	$12.56B	$761.41M	290.55	730

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:LNTH) was last updated on 10/16/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Lantheus (LNTH) Competitors

LNTH vs. VTRS, JAZZ, NBIX, CORT, and ELAN

How does Lantheus compare to Viatris?

Summary

How does Lantheus compare to Jazz Pharmaceuticals?

Summary

How does Lantheus compare to Neurocrine Biosciences?

Summary

How does Lantheus compare to Corcept Therapeutics?

Summary

How does Lantheus compare to Elanco Animal Health?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

LNTH vs. The Competition

Lantheus Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Lantheus (LNTH) Competitors

LNTH vs. VTRS, JAZZ, NBIX, CORT, and ELAN

How does Lantheus compare to Viatris?

Which has more volatility & risk, VTRS or LNTH?

Do institutionals and insiders believe in VTRS or LNTH?

Which has higher valuation and earnings, VTRS or LNTH?

Does the media refer more to VTRS or LNTH?

Is VTRS or LNTH more profitable?

Do analysts prefer VTRS or LNTH?

Summary

How does Lantheus compare to Jazz Pharmaceuticals?

Which has stronger earnings and valuation, LNTH or JAZZ?

Which has more volatility & risk, LNTH or JAZZ?

Does the media prefer LNTH or JAZZ?

Do institutionals & insiders believe in LNTH or JAZZ?

Do analysts rate LNTH or JAZZ?

Is LNTH or JAZZ more profitable?

Summary

How does Lantheus compare to Neurocrine Biosciences?

Does the media refer more to NBIX or LNTH?

Which has stronger valuation and earnings, NBIX or LNTH?

Which has more volatility and risk, NBIX or LNTH?

Is NBIX or LNTH more profitable?

Do analysts prefer NBIX or LNTH?

Do insiders & institutionals hold more shares of NBIX or LNTH?

Summary

How does Lantheus compare to Corcept Therapeutics?

Is LNTH or CORT more profitable?

Do analysts prefer LNTH or CORT?

Do institutionals and insiders have more ownership in LNTH or CORT?

Which has more volatility & risk, LNTH or CORT?

Which has preferable valuation and earnings, LNTH or CORT?

Does the media favor LNTH or CORT?

Summary

How does Lantheus compare to Elanco Animal Health?

Do analysts prefer LNTH or ELAN?

Does the media refer more to LNTH or ELAN?

Do institutionals & insiders hold more shares of LNTH or ELAN?

Which has more risk and volatility, LNTH or ELAN?

Which has higher valuation & earnings, LNTH or ELAN?

Is LNTH or ELAN more profitable?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

LNTH vs. The Competition

Lantheus Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools